Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 28;14:3983–3993. doi: 10.2147/DDDT.S264077

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Yao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The effect of compound 7594–0037 on bortezomib resistance. (A) Proliferation analysis of RPMI-8226/BTZ100 and U266/BTZ100 cells treated with compound 7594–0037 at different concentrations. (B) RPMI-8226/BTZ100 and U266/BTZ100 cells were treated with compound 7594–0037 at different time intervals, and cell viability was measured by CCK-8. (C–D) The apoptosis of RPMI-8226/BTZ100 cells treated with different doses of compound 7594–0037 was detected by the Annexin V/PI kit based on flow cytometry. (E) RPMI-8226 cells were treated with compound 7594–0037 alone or in combination with BTZ, and flow cytometry analysis was performed to determine the cell apoptotic ratio. Error bars: mean ± SD; *, P<0.05; **, P<0.01.